Replies to post #107622 on Biotech Values

[palindromy]

Anybody have an opinion on the risk/reward of BIOD now that valuation is about 50m?
It does seem like the drug does work. If I were mgmt, I would sell or partner right now to fund the new trials and get support on better execution. The upside seems very large while downside has more or less been realized. Of course, you do have to hold for 1-2 years!

[biomaven0]

>BIOD

I hadn't been following them closely, but my impression had been that they were claiming the FDA was OK with the exclusion.

Here's a decent discussion of the Indian data, with some links to some analyst coverage of the issue:

http://seekingalpha.com/article/225291-biodel-s-linjeta-should-overcome-the-usual-fda-approval-hurdles

The same author that wrote that piece also had a piece arguing that Sanofi would license the product.

Peter